Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Free Cash Flow (2019 - 2025)

Addex Therapeutics' Free Cash Flow history spans 7 years, with the latest figure at $723.2 billion for Q2 2025.

  • On a quarterly basis, Free Cash Flow fell 70.2% to $723.2 billion in Q2 2025 year-over-year; TTM through Dec 2025 was $57.3 billion, a 136.5% increase, with the full-year FY2025 number at -$2.6 million, up 57.32% from a year prior.
  • Free Cash Flow came in at $723.2 billion for Q2 2025, up from -$665.9 billion in the prior quarter.
  • The five-year high for Free Cash Flow was $8301.5 billion in Q4 2023, with the low at -$6175.0 billion in Q3 2024.
  • Historically, Free Cash Flow has averaged -$1.8 billion across 5 years, with a median of -$3.2 million in 2021.
  • Biggest five-year swings in Free Cash Flow: surged 260252303.35% in 2023 and later crashed 98657638.52% in 2024.
  • Year by year, Free Cash Flow stood at -$3.2 million in 2021, then increased by 1.42% to -$3.2 million in 2022, then skyrocketed by 260252303.35% to $8301.5 billion in 2023, then fell by 26.45% to $6105.7 billion in 2024, then plummeted by 88.16% to $723.2 billion in 2025.
  • Business Quant data shows Free Cash Flow for ADXN at $723.2 billion in Q2 2025, -$665.9 billion in Q1 2025, and $6105.7 billion in Q4 2024.